Titlebook: Quantity Surveying Practice; Ivor H. Seeley Textbook 1997Latest edition Ivor H. Seeley 1997 construction.environment.industry.project mana

只看該作者 · 發(fā)表于 2025-3-21 16:49:11

書目名稱Quantity Surveying Practice影響因子(影響力)

書目名稱Quantity Surveying Practice影響因子(影響力)學科排名

書目名稱Quantity Surveying Practice網(wǎng)絡公開度

書目名稱Quantity Surveying Practice網(wǎng)絡公開度學科排名

書目名稱Quantity Surveying Practice被引頻次

書目名稱Quantity Surveying Practice被引頻次學科排名

書目名稱Quantity Surveying Practice年度引用

書目名稱Quantity Surveying Practice年度引用學科排名

書目名稱Quantity Surveying Practice讀者反饋

書目名稱Quantity Surveying Practice讀者反饋學科排名

只看該作者 · 發(fā)表于 2025-3-21 22:49:36

Ivor H. Seeley BSc (Est Man), MA, PhD, FRICS, CEng, FICE, FCIOB, FCIH pharmacological testing of the selected compound in high doses in tests directed at indications other than the intended indication of the new compound. These tests were followed by pharmacokinetic studies, which were mainly aimed at confirming of a suitable half-life time and at oral activity. Safe

只看該作者 · 發(fā)表于 2025-3-22 02:32:29

Ivor H. Seeley BSc (Est Man), MA, PhD, FRICS, CEng, FICE, FCIOB, FCIH pharmacological testing of the selected compound in high doses in tests directed at indications other than the intended indication of the new compound. These tests were followed by pharmacokinetic studies, which were mainly aimed at confirming of a suitable half-life time and at oral activity. Safe

只看該作者 · 發(fā)表于 2025-3-22 05:45:38

Ivor H. Seeley BSc (Est Man), MA, PhD, FRICS, CEng, FICE, FCIOB, FCIH in drug finding, drug development and decision making in th.Safety aspects have become an outstanding issue in the process of drug discovery and development. Until 15 years ago safety aspects were addressed by pharmacological testing of the selected compound in high doses in tests directed at indic

只看該作者 · 發(fā)表于 2025-3-22 09:52:43

只看該作者 · 發(fā)表于 2025-3-22 16:52:15

Ivor H. Seeley BSc (Est Man), MA, PhD, FRICS, CEng, FICE, FCIOB, FCIH in drug finding, drug development and decision making in th.Safety aspects have become an outstanding issue in the process of drug discovery and development. Until 15 years ago safety aspects were addressed by pharmacological testing of the selected compound in high doses in tests directed at indic

只看該作者 · 發(fā)表于 2025-3-22 18:10:26

只看該作者 · 發(fā)表于 2025-3-22 21:27:29

Ivor H. Seeley BSc (Est Man), MA, PhD, FRICS, CEng, FICE, FCIOB, FCIH pharmacological testing of the selected compound in high doses in tests directed at indications other than the intended indication of the new compound. These tests were followed by pharmacokinetic studies, which were mainly aimed at confirming of a suitable half-life time and at oral activity. Safe

只看該作者 · 發(fā)表于 2025-3-23 05:23:43

只看該作者 · 發(fā)表于 2025-3-23 07:13:02

		自動登錄	找回密碼
密碼			To register

關于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點評	投稿經(jīng)驗總結	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學	Yale Uni.	Stanford Uni.
\|Archiver\|手機版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-17 10:23
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權所有 All rights reserved